DTIL Stock Analysis: Buy, Sell, or Hold?
DTIL - Precision BioSciences, Inc. Common Stock
$7.13
0.14 (2.00%)
▲
5d:
-1.66%
30d:
-12.84%
90d:
-2.06%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
2d
Get Alerted When DTIL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: DTIL shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: DTIL shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: DTIL is currently trading at $7.13, which is considered slightly low relative to its 30-day fair value range of $7.10 to $8.61.
Technical Outlook: Technically, DTIL is in a uptrend. Immediate support is located at $6.70, while resistance sits at $7.73.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.60 (+323.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DTIL is in a uptrend. Immediate support is located at $6.70, while resistance sits at $7.73.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.60 (+323.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$7.10 -
$8.61
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 323.5% below Wall St target ($29.60)
Trading Range Analysis
30-Day Trading Range
$7.10 -
$8.61
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$1.13
(15.8%)
Support & Resistance Levels
Support Level
$6.70
Resistance Level
$7.73
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.69
Wall Street Target
$29.60
(+323.5%)
Revenue Growth (YoY)
37272.4%
Profit Margin
-96.7%
Share & Embed Analysis
Last updated: August 03, 2026 3:13 PM ET
Data refreshes hourly during market hours. Next update: 4:13 PM
Data refreshes hourly during market hours. Next update: 4:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DTIL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
J. Jefferson Smith
SELL
4925 shares
2026-02-18
John Alexander Kelly
SELL
8149 shares
2026-02-18
Michael Amoroso
SELL
20559 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
